Older muscles become resistant to adiponectin's beneficial metabolic effects

Adiponectin is a hormone secreted by fat tissue that normally improves insulin sensitivity and metabolic health. This study, using both human tissue samples and cell culture experiments, demonstrates that skeletal muscle becomes progressively resistant to adiponectin's beneficial effects with aging. The researchers found that older adults' muscle tissue showed blunted responses to adiponectin signaling despite normal or even elevated circulating adiponectin levels—a phenomenon similar to insulin resistance. In vitro experiments with muscle cells from different-aged donors confirmed the age-dependent decline in adiponectin responsiveness. This resistance may help explain why older adults are more prone to metabolic dysfunction, type 2 diabetes, and difficulty maintaining muscle mass even when adiponectin levels aren't low. The finding suggests that simply boosting adiponectin levels (through exercise, weight loss, or future therapeutics) may not be enough in older individuals—we may need interventions that restore muscle tissue's sensitivity to the hormone. Understanding the molecular mechanisms behind this resistance could reveal new therapeutic targets for preserving metabolic health during aging. It's another example of how aging involves not just declining beneficial factors, but tissue-level resistance to signals that remain present.